Lupin strengthens board with appointment of Jeffrey Kindler and Alfonso 'Chito' Zulueta as Independent Directors

Lupin appoints ex-Pfizer CEO Jeffrey Kindler and Alfonso 'Chito' Zulueta as independent directors. Kindler brings 40 years of experience, including leadership roles at Pfizer, McDonald's, and General Electric. Zulueta has held positions at Interpharma Investments, CZ Ventures, and Eli Lilly and Company. Their industry expertise will support Lupin's growth plans.


PTI | New Delhi | Updated: 09-05-2024 12:47 IST | Created: 09-05-2024 12:47 IST
Lupin strengthens board with appointment of Jeffrey Kindler and Alfonso 'Chito' Zulueta as Independent Directors
  • Country:
  • India

Pharma major Lupin Ltd on Thursday announced appointments of ex-Pfizer Chairman and CEO, Jeffrey Kindler and Alfonso 'Chito' Zulueta as independent directors on its board.

Kindler is currently the CEO of Centrexion Therapeutics, a privately-held biotechnology company, Senior Advisor to Blackstone, Operating Partner at ARTIS Ventures and Global Chair of GLG Institute, Lupin said in a regulatory filing.

He brings over four decades of business experience holding leadership positions at some of the world's most recognised companies, including Pfizer, where he served as Chairman & Chief Executive Officer, as well as McDonald's Corporation and General Electric Company, the company added.

Before that, he was a partner at law firm Williams & Connolly.

Zulueta currently serves as Non-Executive Chairman of the board of directors of Interpharma Investments Ltd, the holding company of Zuellig Pharma, one of the largest healthcare services groups in Asia, Lupin said.

He is also President & CEO of CZ Ventures, a company focused on start-up investments, and member of the board of directors at Glooko, CTS Corporation, and Bridge PayDay Solutions.

He spent over three decades in various roles of increasing responsibility with Eli Lilly and Company, it added.

''Their extensive experience in building healthcare institutions, strategic perspectives of our industry and deep understanding of the evolving global pharmaceutical landscape, will enable us to advance our growth plans in the years to come,'' Lupin CEO, Vinita Gupta said.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback